US real pricing gains are the single largest driver of global revenue growth for a typical biopharma multinational. Growing rebates account for the expanding list-to-net gap. Rebates vary greatly by product category; as such companies’ relative rates of net pricing gain are largely determined by the categories in which they compete, and their products’ differentiation levels within these categories

Given the growing divergence between list and net, and the variance in rebate levels across product categories, it is essential to be able to see both list and net pricing by product, by product category, and by company

Our US brand pricing dataset consists of list and net pricing for approximately 1,000 brand drugs with disclosed US product-level sales from approximately 100 currently or previously publicly-traded firms. For each product, we capture list pricing and unit volume, and calculate net pricing, by quarter as far back as 1Q07. Products are aggregated by therapeutic category (e.g. HCV, COPD, etc.) to allow analysis of competitive pricing, by company, by company type (large cap, biotech, spec pharma) and by molecule type (large v. small). The tool allows us to determine the contribution of US net pricing to companies’ overall revenue growth, and to identify companies with more or less stable US net pricing outlooks

For username / password credentials, please contact us.

Last Updated: 3/22/2024: The Excel-based version of the model no longer published or supported by SSR Health. Limited data tables from that file are available to subscribers who received the Excel-based version before the transition to Tableau Online

USBrandPriceTool_4Q23